|Articles|July 18, 2019

Management of ocular inflammation and pain using novel insert

ICMYI: Dr. Tyson shares his pearls using the dexamethasone 0.4 mg insert (Dextenza, Ocular Therapeutix).

Sydney Tyson, MD, shares the take-home message from the presentation he delivered at the 2019 American Society of Cataract and Refractive Surgery meeting: "Management of Ocular Inflammation and Pain Following Cataract Surgery with Dexamethasone 0.4 mg Insert (Dextenza, Ocular Therapeutix)."

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Management of ocular inflammation and pain using novel insert

Related Content

Beyond the Walls: Leading with love, loyalty, and a team first philosophy with Vance Thompson, MD

Beyond the basics: John Berdahl, MD, on AI-driven IOL planning, PCO prevention, and lessons from the mission field

Closing the gap: John Berdahl, MD, on the global cataract burden and the emerging dementia connection

Contaminated trypan blue solution linked to fungal endophthalmitis outbreak after cataract surgery

Smoking identified as significant risk factor for vision-threatening ocular outcomes

Latest CME

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Retina Updates in Montréal

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought echanisms

Reasoning prompts sharpen multimodal AI on bilingual ophthalmology exam questions

TECNIS PureSee IOL launches in US following FDA approval for cataract surgery

Phase 3 NORTHSTAR trial launches for gildeuretinol in stargardt disease

Beyond the Walls: Leading with love, loyalty, and a team first philosophy with Vance Thompson, MD